Histology is the gold standard for diagnosis of melanoma. It determines prognosis and therapeutic approach but is susceptible to interpretation bias by the pathologist/dermatopathologist (P/DP).

In order to standardize histologic reports in melanoma and to decrease bias, the International Collaboration on Cancer Reporting (ICCR) suggests the following mandatory elements for inclusion in these reports: involvement and distance of margins, presence or absence of dermal invasion, Breslow index for invasive cases, mitotic index, presence or absence of ulceration, and presence or absence of microsatellitosis.1

The latest guidelines on melanoma of the Brazilian Dermatology Society (SBD) recommend histologic review by a P/DP experienced in melanocytic lesions whenever possible before indicating treatment.2

This study’s objective was to assess whether histologic review of melanoma cases performed by a P/DP experienced in melanocytic lesions leads to changes in therapeutic approach.

A retrospective study was conducted in a private clinic in São Paulo, Brazil, covering a 25-year span (1991-2016).

The clinic works routinely with three pathology laboratories that are known for their expertise in dermatologic oncology and melanocytic lesions. Reports from other laboratories were reviewed whenever the result specified melanoma or when a melanocytic lesion could not be classified clearly as benign, premalignant, or malignant.

There were 145 diagnoses of melanoma during the period, of which 21.4% (n = 31) were submitted to review by an expert pathologist in melanocytic lesions. The original and revised reports were compared as to TNM classification, diagnosis, and implications for treatment approach.

After histologic review there was no change in TNM classification in 13 (41.9%) cases, nor was treatment approach altered.

Differences in histologic reports were observed in 58.1% (n = 18) of the reviewed cases. TNM classification changed in 38.7% (n = 12) of the cases. Of these, the main differences in reports leading to to changes in TNM classification referred to: Breslow index in 91.7% (n = 11); mitotic index in 58.3% (n = 7); and Clark level in 33.3% (n = 4) (Table 1).

Diagnostic discordance occurred in 19.3% (n = 6) of the cases. Four cases with initial diagnosis of dysplastic nevus had diagnosis revised to in situ melanoma (upstaging), and two cases initially diagnosed as in situ melanoma had diagnosis revised to junctional nevi (downstaging) (Table 1 and Figure 1A).

Figure 1.

A - Concordance between initial/review reports of 31 melanoma cases and change in diagnosis/TNM classification; B - evaluation of change in treatment approach in melanoma cases submitted to histologic review

(0,05MB).

Histologic review led to change in treatment approach in 41.9% of cases (n = 13). Changes consisted of indication versus non-indication of sentinel lymph node biopsy (SLN) and modification urgical margin size. In more than half of the cases in which there was a change in treatment approach (53.8%; n = 7), the new approach was less invasive (Figure 1B).

Performed at findings from this study in a private clinic specialized in dermatologic oncology in São Paulo is in accordance with those of other studies in dermatologic oncology centers around the world.

Present literature shows that histologic review can lead to change in diagnosis in nearly one-fifth of cases; in the current study, diagnosis was changed in 19.3% of cases, a proportion within the range from 2.9% to 27% reported in previous studies.3–10

Among cases where melanoma diagnosis was confirmed by revision, TNM classification changed in 38.7%. Although change in histologic staging is frequently seen in literature, rates are lower than those observed in the present study. In studies performed in cancer referral centers in the United States and Australia, the proportion of staging change varied from 22.1% to 24%.3,4 In these two referral centers, it is common practice to order histologic review of all incoming referrals before initiating treatment.

Our findings may have a bias due to the lack of specific criteria for selecting cases for review. Future studies might also consider joint review by pathologists who evaluated the case (first histology and review) in order to reach an agreement, or even a review by two P/DPs in order to increase diagnostic accuracy.

The main changes in treatment approach, corroborating other studies, were change in the size of surgical margins and indication or not of SLN biopsy (dictated manly by changes in the mitotic index or Breslow thickness).3,4

One unique finding in this study was that the majority of therapeutic changes resulting from the reviews led to less invasive, approach, a finding not reported previously in literature.

Based on the current findings, we conclude that the review of histologic examination in melanoma by a P/DP experienced in melanocytic lesions altered the treatment approach in 41.9%, making it less invasive in the majority of these cases.

Our study supports the recommendation in the SBD guidelines in favor of a second opinion by an expert pathologist in melanoma cases.

Financial support: None.

Conflict of interest: None.